Patents by Inventor Suzanne Suchard

Suzanne Suchard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170306034
    Abstract: Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.
    Type: Application
    Filed: September 10, 2015
    Publication date: October 26, 2017
    Inventors: Marek HONCZARENKO, Vaishali SHAH, Lixin LANG, Urvi ARAS, Diane SHEVELL, Christine KRATT, Karen PRICE, Suzanne SUCHARD
  • Publication number: 20170015754
    Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
    Type: Application
    Filed: September 8, 2016
    Publication date: January 19, 2017
    Inventors: Anish SURI, Steven SHERIFF, Suzanne SUCHARD, Aaron YAMNIUK, Stanley KRYSTEK, James TAMURA, James BRYSON, Steven GRANT, Philip DREW
  • Patent number: 9475879
    Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: October 25, 2016
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, DOMANTIS LIMITED
    Inventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
  • Publication number: 20140099317
    Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
    Type: Application
    Filed: April 20, 2012
    Publication date: April 10, 2014
    Applicants: DOMANTIS LIMITED, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
  • Publication number: 20060014180
    Abstract: The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Application
    Filed: June 2, 2005
    Publication date: January 19, 2006
    Inventors: Donald Jackson, Chandra Ramanathan, John Feder, Gabe Mintier, Liana Lee, Thomas Nelson, Nathan Siemers, David Bol, Suzanne Suchard, Gary Schieven, Joshua Finger, C. Todderrud, Donna Bassolino, Stanley Krystek, Dana Banas, Patrick McAtee
  • Patent number: 6939896
    Abstract: Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection.
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: September 6, 2005
    Assignee: AstraZeneca AB
    Inventors: Marc Jerome Chapdelaine, Katherine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
  • Publication number: 20050130286
    Abstract: The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Application
    Filed: December 20, 2001
    Publication date: June 16, 2005
    Inventors: Donald Jackson, Chandra Ramanathan, John Feder, Gabe Mintier, Liana Lee, Thomas Nelson, Nathan Siemers, David Bol, Suzanne Suchard, Gary Schieven, Joshua Finger, C. Todderrud, Donna Bassolino, Stanley Krystek, Dana Banas, Patrick McAtee
  • Publication number: 20030207812
    Abstract: Substituted phenanthrene-9,10-diones in accord with structural diagram I, 1
    Type: Application
    Filed: November 25, 2002
    Publication date: November 6, 2003
    Inventors: Marc Jerome Chapdelaine, Katharine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
  • Publication number: 20030130298
    Abstract: Heterocyclic dione compounds as disclosed in the specification, compositions thereof and methods for the use thereof, for the treatment of T cell-mediated conditions such as autoimmune diseases and organ graft rejection.
    Type: Application
    Filed: November 25, 2002
    Publication date: July 10, 2003
    Inventors: Marc Jerome Chapdelaine, Katherine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
  • Publication number: 20030119897
    Abstract: Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, wherein: Q1 at each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C1-C3) alkyl and C(O)phenyl, and Q2 is selected from hydrogen, halogen, O—(C1-C3)alkyl, O—(C1-C3)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NO2 or halogen, and indolyl may be substituted with (C1-C3)alkyl or phenyl.
    Type: Application
    Filed: November 13, 2002
    Publication date: June 26, 2003
    Inventors: Marc Jerome Chapdelaine, Katherine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale